Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTAN
  • Sponsors Aragon Pharmaceuticals; Janssen Pharmaceutical KK
  • Most Recent Events

    • 06 Nov 2019 Results from two clinical trial SPARTAN (n=1150) first interim analysis data and published data from ARAMIS (n=1509) were presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 27 Sep 2019 Results (n=1207) of second pre-specified interim results assessing overall survival of apalutamide in patients with non-metastatic prostate cancer, published in the Annals of Oncology.
    • 27 Sep 2019 According to a Janssen Pharmaceuticals media release, data from this study was presented at the 2019 European Society for Medical Oncology (ESMO) Annual Congress , and simultaneously published in Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top